The sphingolipid activator proteins (saposins A, B, C and D) are small homologous glycoproteins that are encoded by a single gene in tandem within a large precursor protein (prosaposin) and are required for in vivo degradation of some sphingolipids with relatively short carbohydrate chains. Human patients with prosaposin or specific saposin B or C deficiency are known, and prosaposin-and saposin A-deficient mouse lines have been generated. Experimental evidence suggests that saposin D may be a lysosomal acid ceramidase activator. However, no specific saposin D deficiency state is known in any mammalian species. We have generated a specific saposin D 2/2 mouse by introducing a mutation (C509S) into the saposin D domain of the mouse prosaposin gene. Saposin D 2/2 mice developed progressive polyuria at around 2 months and ataxia at around 4 months. Pathologically, the kidney of saposin D 2/2 mice showed renal tubular degeneration and eventual hydronephrosis. In the nervous system, progressive and selective loss of the cerebellar Purkinje cells in a striped pattern was conspicuous, and almost all Purkinje cells disappeared by 12 months. Biochemically, ceramides, particularly those containing hydroxy fatty acids accumulated in the kidney and the brain, most prominently in the cerebellum. These results not only indicate the role of saposin D in in vivo ceramide metabolism, but also suggest possible cytotoxicity of ceramide underlying the cerebellar Purkinje cell and renal tubular cell degeneration.
INTRODUCTION
The physiological functions of sphingolipids are drawing attention because of their newly found functions in variety of cellular processes including proliferation, differentiation, apoptosis and cellular senescence (1) (2) (3) . Many of the lysosomal diseases are caused by abnormal catabolism of sphingolipids, resulting in severe neurological dysfunction (4) . However, very little is known about the distinct pathophysiology of abnormal sphingolipid metabolism in the nervous system of individual lysosomal diseases.
Sphingolipid activator proteins (saposins A, B, C and D) are small homologous glycoproteins derived from a common precursor protein (prosaposin) encoded by a single gene (5) . They are specifically required for in vivo degradation of sphingolipids with short carbohydrate chains. Human patients of the prosaposin deficiency and the specific saposin B or C deficiencies are known (6, 7) . In addition, we have previously 2709-2723 doi:10.1093/hmg/ddh281 Advance Access published on September 2, 2004 generated a mouse model of prosaposin deficiency (8) and also have recently generated a saposin A deficient mouse line that exhibits the clinical/pathological/biochemical phenotype of a late-onset, chronic form of globoid cell leukodystrophy (9, 10) . This confirmed earlier suggestions and provided definitive evidence that saposin A is indispensable for normal catabolism of galactosylceramidase substrates and that normal cellular functions cannot be maintained in its absence, although human patients with specific saposin A deficiency have not yet been known. Although there is experimental evidence suggesting that saposin D is an acid ceramidase activator (5, 11, 12) , it is unclear whether saposin D is indispensable for normal cellular function. No human patients or animal models with specific saposin D deficiency are known.
In order to clarify the physiological function of saposin D, we have generated and characterized a line of a specific saposin D mutant mouse. This mutant shows a complex clinical/biochemical/pathological phenotype in the cerebellum and kidney. In this report, we describe the phenotype of the specific saposin D 2/2 mouse and discuss the physiological functions of saposin D with respect to the in vivo ceramide metabolism, which may have a specific relevance to the pathogenesis of the unusual selective degeneration of cerebellar Purkinje cells.
RESULTS

Generation of the saposin D 2/2 strain
The targeting vector was designed to introduce a mutation in exon 13 that changes the 5th cysteine in saposin D to serine, resulting in destruction of one of the three disulfide bridges in saposin D (Fig. 1A) . Correctly targeted embryonic stem (ES) cells, before and after removal of the neomycin resistance gene (Neo) by Cre recombinase, and genotypes of resultant mice were confirmed by appropriate DNA analyses ( Fig. 1B and C). The allele with the C509S mutation in the saposin D domain generated stable prosaposin mRNA of normal length, as expected, in contrast to its absence in the prosaposin deficiency (Fig. 1D ). It should be noted that two lines of saposin D 2/2 mice were generated originating from two different targeted ES cell lines. No phenotypic differences have so far been detected between the two mutant lines.
Clinical phenotype
Viable saposin D 2/2 mice were born with the frequency expected from the Mendelian single gene inheritance of autosomal recessive nature. Both male and female mice were fertile, and females were able to raise their offspring normally. Since there is experimental evidence suggesting that saposin D is an acid ceramidase activator (5, 11, 12) , we hoped to see clinical phenotype similar to human acid ceramidase deficiency (Farber disease) (13) . However, no skin nodules, joint involvements or hepatosplenomegaly, which are the hallmarks of human Farber disease, were observed. Unexpectedly, saposin D 2/2 mice developed progressive polyuria (more than 20 times normal) with polydipsia at around 2 months and some mice died of severe dehydration ( Fig. 2A and B) . Saposin D 2/2 mice began to show impairment in the motor coordination tasks around 4 months and apparent ataxia around 6 months suggesting cerebellar dysfunction. These clinical abnormalities could be demonstrated by paw prints and the runway test ( Fig. 2C and D) . Gait disturbance progressed and the majority of affected mice could hardly move at their terminal stage around 15 months. We estimate that the maximum life span of saposin D 2/2 mice is about 500 days.
Pathological phenotype
Histologically, kidneys of saposin D 2/2 mice showed various degrees of renal tubular degeneration. In contrast, renal glomeruli were relatively spared (Fig. 3) . In their terminal stage at around 15 months, it was grossly apparent that the renal cortex was significantly thinned with an enormously dilated renal pelvis, indicative of hydronephrosis (Fig. 3A) . In the liver, spleen and testis of saposin D 2/2 mice, no apparent pathological changes were observed (data not shown).
The external aspects of the brain and the trigeminal and sciatic nerves of saposin D 2/2 mice were grossly indistinguishable from those of their wild-type littermates. In their terminal stage around 15 months, the cerebellum of saposin D 2/2 mice was smaller size than that of their wild-type littermates (data not shown). By basic histological analyses at around 3 months, the cerebellar cortex of saposin D 2/2 mice had the normal layering pattern-the outer molecular layer containing the Purkinje cell dendrites arranged in parasagittal fans, the single cell layer of the Purkinje cell bodies and the internal granule cell layer containing the small granule neurons. Loss of the Purkinje cells was first observed at around 4-5 months and progressed to the terminal stage. Majority of the cerebellar Purkinje cells disappeared at the terminal stage around 15 months (Fig. 4) . At the terminal stage, conspicuous aggregations of apparent storage cells were observed around the blood vessels in the white matter of the cerebellum and the spinal cord (Fig. 4) . These 'storage' cells contained periodic acid Schiff (PAS)-positive materials. In the spinal cord, the storage cells were more conspicuous on the dorsal side (Fig. 4) .
Detailed analyses by immunohistochemistry revealed progressive and patterned loss of cerebellar Purkinje cells only in the saposin D 2/2 mice, never in the wild-type littermates (Fig. 5 ). In the immunostaining with an anti-calbindin D28k antibody as a Purkinje cell marker, the cerebellum of 10-month-old saposin D 2/2 mouse showed conspicuous patterned loss of the Purkinje cell bodies and dendrites in contrast to the regularly arranged Purkinje cell bodies and their fine axons and dendrites in the molecular layer both in the parasagittal and coronal sections of wild-type littermates. In the parasagittal sections, the survived Purkinje cells were concentrated in dorsal lobe vermis of the cerebellum (Fig. 5A -D) . In the coronal sections, the survived calbindin immunopositive Purkinje cells aligned in stripes (Fig. 5E-H) .
Further multiple immunostaining using confocal microscopic analysis indicated the selective loss of Purkinje cells of the saposin D 2/2 mice (Fig. 6) . In contrast to the progressive degeneration of cerebellar Purkinje cells, the other surrounding GABA-neurons and astroglial cells including Bergmann glia, were well preserved. The density of GAD65/67 immuno-positive GABA-neurons in the molecular layer was similar to that of the wild-type ( 
Biochemical phenotype
In view of the suggested function of saposin D as an activator for in vivo degradation of ceramide, we analyzed the brain, kidney and liver tissues from homozygous mutant mice at 40 days and 5, 10, 13 months for their lipid composition by thin-layer chromatography (TLC) and compared with those of wild-type littermates, saposin A 2/2 mice, and 39-day-old prosaposin 2/2 mice. An alkaline-resistant lipid, which moved more slowly than ceramides containing non-hydroxy fatty acids (NFA/d18:1), was detected in the kidney and brain of saposin D 2/2 mice. (Fig. 7A ). By liquid secondary ion and electrospray ionization mass spectrometry, this lipid was identified as ceramide containing 2-hydroxy fatty acids and 4-sphingenine (HFA/d18:1), which was barely detectable in the wild-type mice (Fig. 7A ). In the kidney of saposin D
2/2
mice, other molecular species, which consisted of HFA and 4-hydroxysphiganine (HFA/t18:0) (14,15) were also increased ( Fig. 7A and B, Table 1 ). The structures of ceramides were further confirmed by low energy collision-induced dissociation of the [M 2 H] 2 ions, which produced product ions referring to the identities of the fatty acid substituent and of the sphingoid base (Figs 8 and 9) (16). Ceramides containing non-hydroxy fatty acids (NFA/d18:1), which accumulated in the tissue of human Farber disease (17 -20) , also increased in saposin D 2/2 mice but to a lesser extent (up to 220% in the kidney and 130% in the brain) ( Fig. 7 ; Table 1 ). The accumulation of HFA-ceramide (HFA/d18:1) was already evident at 40-day in the kidney of saposin D 2/2 mice in a similar degree observed in the kidney of prosaposin 2/2 mice where the major accumulation was observed for non-hydroxy fatty acid-containing ceramides ( Fig. 7B ; Table 1 ). In the brain of saposin D 2/2 mice, the accumulation was first detected around 6-7 months and the accumulation was more prominent in the cerebellum than in the cerebrum ( Fig. 7A and C) . No accumulation was observed in the brain of saposin A 2/2 mice (Fig. 7C) . Consistent with the absence of histopathological changes, there was no accumulation of HFA-ceramide in the liver ( Fig. 7A ; Table 1 ). No major abnormalities in the profile of other lipids including sulfatides and gangliosides were found in saposin D 2/2 mice, except for dihexosylceramide, which increased 2-3 times in the kidney (data not shown).
DISCUSSION
Earlier, the gene targeting technology allowed us to generate mouse models of prosaposin deficiency (8) and saposin A deficiency (9, 10) . Phenotype of the prosaposin-deficient mice closely mimicked that of human prosaposin deficiency, whereas the specific saposin A knockout mouse established saposin A as a physiologically essential activator of galactosylceramidase in the sense that normal metabolism of its substrates cannot be maintained in its absence. The saposin A 2/2 mice showed a clinical, pathological and biochemical phenotype that is qualitatively identical to that of the twitcher mutant due to a genetic galactosylceramidase defect. In the study described here, we asked an equivalent question as we asked when we generated the saposin A 2/2 mouse, "What would be the in vivo consequences of specific absence of saposin D?" There is a series of in vitro and cell culture evidence in the literatures suggesting that saposin D might be a physiological activator of lysosomal acid ceramidase (5, 11, 12) .
We utilized the same experimental design as we used for the saposin A inactivation (9) . The targeting construct had two features in addition to the standard inclusion of the Neo gene and thymidine kinase gene for double selection of correctly targeted ES cells; presence of the loxP sequences flanking the Neo gene within an intron for later removal of Neo, and a newly generated XhoI site for convenient genotyping. Even though the Neo gene was within an intron, we removed it because the presence of a foreign sequence of the size of the Neo gene would have been likely to result in an abnormal splicing and an unstable expression. We had considered application of Cre recombinase in vivo using Cre transgenic mice but eventually chose to remove Neo gene at the stage of targeted ES cells. Application of Cre recombinase using transient transfection of the Cre expression plasmid removed the Neo gene efficiently from ES cells. The single loxP sequence left in within the intron appeared to have no ill effect in the splicing judged from the size and stability of prosaposin mRNA.
The phenotype of saposin D 2/2 mice turned out to be much more complex than we had anticipated. Saposin D 2/2 mice were born and grew apparently normally. There were no subcutaneous nodules characteristic of human patients with Farber disease due to acid ceramidase deficiency (13) . Phenotypic abnormalities did not become obvious until affected mice were well into their adulthood. Both males and females were fertile and females were able to raise their pups normally. However, two phenotypic abnormalities stood out that were relatively subtle but slowly progressive; the renal abnormalities and the central nervous system (CNS), particularly cerebellar abnormalities. At this time, the metabolic relationship between the renal and the CNS pathology is unclear. Our expectation for a mouse model of human Farber disease due to saposin D deficiency was clearly optimistic. There are no skin lesions. Although ceramide, particularly HFAceramide, does accumulate abnormally, it is much lesser than the massive accumulation seen in human Farber disease, and perhaps more importantly, the accumulation is selective among different organs. Substantial accumulation of HFA-ceramide occurs in the brain and kidney but not in the liver. Cultured fibroblasts from saposin D 2/2 mice did not show accumulation of either ceramide (data not shown). Thus, the saposin D 2/2 mouse is not an appropriate model of human Farber disease. Perhaps the simplest explanation is that: (a) one or more of saposins other than saposin D also functions as ceramidase activator in vivo and that specific saposin D deficiency results in partial defect in degradation of ceramide and/or (b) saposin D may have more affinity with HFA-ceramide than NFA-ceramide and may be more Recently, novel function of saposin C for lipid antigen presentation through CD1b to human T-cell was identified (21 -23) . Vaccaro and coworkers also demonstrated that saposin D, like saposin C, also strongly binds to membranes and that anionic phospholipids promote and modulate its interaction with lipid surfaces (24 -26) . On the basis of these pieces of in vitro evidence, the role played by saposin D may be more general than promoting sphingolipid degradation, e.g. the saposin D might also be a key mediator of the solubilization of intralysosomal/late endosomal anionic phospholipid-containing membrane. Further investigation to define the physiological function of saposin D itself in the cerebellum and kidney is of interest.
We had not anticipated the kidney involvement, including dramatic polydipsia, polyuria, dehydration and eventual hydronephrosis nor can we explain the metabolic basis for these observations. It can be assured, however, that the kidney abnormalities are also due to saposin D deficiency, because the phenotype is identical between the two separate lines of saposin D deficient mice generated from two different targeted ES cells. The wild-type or heterozygous littermates never showed the renal abnormalities. Both males and females exhibited basically similar kidney pathology. As it is known that there are gender differences in the lipid profile of the kidney of normal mice (27, 28) , we limited our studies of kidney lipid to males in this series. Experimental evidence exists regarding the physiological function of sphingolipids or ceramide in proliferation, apoptosis and transport abnormalities associated with cystic renal disease. Altered sphingomyelinase and ceramide expressions were demonstrated in ischemic and nephrotoxic acute renal failure (29 -33) . The pathogenetic mechanism of the renal abnormalities remains for future investigations.
Slowly progressive and specific degeneration of cerebellar Purkinje cells is clearly the most interesting observation in saposin D 2/2 mice. Subtle neurological signs of motor incoordination suggestive of cerebellar involvement appear at around 4 months. The neuropathological counterpart appears to be the specific disappearance of the cerebellar Purkinje cells with relative preservation of other cell types including GABA-neurons and the Bergmann glia (Fig. 6) . The abnormal accumulation of HFA-ceramide is also most conspicuous in the cerebellum. Although very preliminary, saposin D might normally be highly localized in the Purkinje cells (as discussed subsequently). Purkinje cell death in the cerebellum has been observed in several spontaneous and experimental mouse mutants as well as in some human diseases (34) . NiemannPick disease type C (NPC) is an inherited lysosomal disease characterized by hepatosplenomegaly and severe CNS deterioration (35) . In a mouse model of NPC, progressive motor impairment and the corresponding degeneration of cerebellar Purkinje cells occur (36 -38) . The pattern of cerebellar Purkinje cell death in NPC mice is similar to that seen in saposin D 2/2 mice. In calbindin immunostaining in saposin D 2/2 mice, surviving Purkinje cells are arranged in longitudinal strips probably corresponding to the normal longitudinal cerebellar compartmentation (39, 40) . Although further quantitative analyses are needed, the Purkinje cells in the posterior vermis seemed to be relatively resistant. These spatial patterns of the Purkinje cell death suggest differential susceptibility of morphologically similar cells perhaps due to their different molecular phenotypes. Cultured cerebellar Purkinje cells have been shown to require ceramide for survival and dendritic differentiation (41) . In the saposin D 2/2 mice, the Purkinje cells presumably degenerate owing to the impaired degradation of ceramide. Recently, a patterned expression of sphingosine kinase was identified in the cerebellar Purkinje cells (42) . Some other Purkinje cell constituents may also exhibit similar distribution pattern and they may be responsible for the patterned death of the Purkinje cells of saposin D 2/2 mice. The question remains as to whether the accumulation of hydroxyl fatty acid-containing ceramide is mechanistically responsible for the observed renal abnormalities and the Purkinje cell death. Ceramide generated by action of sphingomyelinase has been implicated to play a critical role in the apoptotic pathway (43, 44) . However, the mechanism of ceramide action as an essential death mediator has not been clarified completely (45, 46) . An acid ceramidase knockout mouse showed early embryonic lethality in homozygotes, suggesting the important role of ceramide in vivo (47) . On the other hand, natural ceramide formed in the lysosomal compartment appears to be unable to escape out of the lysosome, which makes it difficult to understand how hydrophobic ceramide could activate protein targets present in the cytosol or other subcellular compartments (48) . These findings strongly suggest that, in contrast to fluorescent derivatives, endogenous long-chain ceramide is unable to exit from lysosomes, therefore making the lysosome-sequestered ceramide unlikely to be a biomodulatory molecule. Burek et al. (46) stimulated cultured cells from patients with the Farber disease with various stress agents and observed no difference in the frequency of apoptosis from control cells. On the other hand, cell-permeable exogenous ceramides had stronger pro-apoptotic activity on the Farber cells than on the control cells. In addition, anti-CD95 induced apoptosis occurred more frequently in the Farber cells. Their data suggest that accumulation of ceramide due to defective acid ceramidase may not play an important role as a mediator in drug-and irradiation-induced apoptosis. Furthermore, the accelerated apoptosis of the Farber cells in response to CD95 ligation might represent its function as facilitator and amplifier of receptor signaling in lipid-rich microdomains. However, in accordance with a role in lipid-rich microdomains, ceramide may function as an amplifier in CD95-mediated apoptosis by altering membrane composition (46) .
A point of uncertainties must be pointed out. The definitive proof that our mouse has specific deficiency of saposin D with other three saposins completely intact is not yet on hand because of the limitation in the present technology. Ideally, it should be demonstrated that only saposin D protein is absent and the other three are normally present by immunochemical means. Laboratory of Dr Grabowski kindly provided us with their rabbit antisera against mouse saposin D (49,50). This antibody gave punctuate staining of the Purkinje cells in wild-type mice, whereas staining was completely negative in the Purkinje cells of saposin D 2/2 mice (Fig. 10) . This is clearly consistent with the specific saposin D deficiency in our mice and in any case positively demonstrates that the Purkinje cells of affected mice lack saposin D. However, we must view this finding as preliminary because the antibody also reacts with the precursor protein, prosaposin. The clear-cut results in the Purkinje cells could not be obtained in other cellular types in the brain. We can interpret this observation that other areas of the brain normally contain higher concentrations of prosaposin, which should also be present in the saposin D 2/2 mouse but the definitive proof must wait for an antibody specific to prosaposin. We, nevertheless, feel comfortable to present the mouse as saposin D 2/2 based on the following several pieces of circumstantial evidence. Equivalent disease-causing mutations that replace one of the strictly conserved cysteines in the saposin B and C domains with phenylalanine or serine are known among human patients. In these patients, it has been shown that the initial translation product is normally processed and only the specific mutated saposin is absent, whereas others are present and functionally intact (5). This was precisely our rationale to introduce this specific mutation into the saposin D domain. Our mouse does not show any of the clinical, pathological or biochemical phenotypes we would have expected if it were also deficient in any of the other three saposins.
In conclusion, we have newly generated saposin D-deficient mice. They not only indicate the role of saposin D in in vivo ceramide metabolism but also suggest possible cytotoxicity of ceramide underlying the cerebellar Purkinje cell and renal tubular cell degeneration. The saposin D 2/2 mice should be a useful new model to study the physiological function of saposin D and ceramide.
MATERIALS AND METHODS
Saposin D targeting vector and generation of the saposin D mutant mice
The targeting strategy that we have used was an approach basically similar to that we used to generate the saposin A 2/2 mice (9). The targeting vector was designed to introduce specific mutations (C509S) in the saposin D domain of the mouse prosaposin gene using Cre/loxP system. This amino acid substitution is expected to destroy one of the disulfide bonds in saposin D (GenBank: U57999) (51). We picked this mutation because equivalent mutations that abolish one of the disulfide bonds in the saposin B and C domains, respectively, are known to result in specific saposin B or C deficiency in humans. Mouse prosaposin gene was cloned from a 129Sv mouse genomic library (Stratagene, La Jolla, CA, USA) as described previously (8) . To construct the targeting vector, three separate gene fragments were subcloned into pBluescript KS(þ) (Stratagene); a 4.0 kb EcoRI-HindIII fragment containing exons 8 and 14 (subclone 3), 7.7 kb EcoRI -SalI fragment containing exons 8 -15 (subclone 7) and a 1.2 kb HindIII -HindIII fragment containing exons 15 (subclone 8). Subclone 7 was used to introduce a fifth Cys to Ser substitution at amino acid position 509 in exon 13 by using the two-oligonucleotide PCR mutagenesis method. The mismatch oligonucleotide sets were: Primer 1; 5 0 -ATGGATCCTGGA TTTGTCTCGAGTGTAAGCCGCGCCAGA-3 0 (containing the unique BamHI site) and Primer 2; 5 0 -GCTGACTCACGT CCCTGAGAAGGAA-3 0 (located outside the unique HindIII site). Underlined letters indicate the mismatched nucleotides. This mutation leads to the substitution of the fifth Cys and destruction of one of the disulfide bonds in saposin D, and simultaneously introduces a unique XhoI recognition site for convenient genotyping. The mutant PCR products were digested with BamHI and HindIII and replaced by the homologous fragment in subclone 3. The targeting construct was generated in the vector, OSdupdel, which contained MC1-neomycin resistance gene (Neo) flanked by two loxP sites and thymidine kinase (TK) under control of 3 0 phosphoglycerate kinase (PGK) (52) . The homologous 4.0 kb EcoRI -SalI fragment from subclone 3 carrying the introduced C509S mutation was ligated to the SfiI-XhoI site of the vector upstream to the Neo selection cassette flanked by two loxP sites to form the 5 0 region of the homology. The homologous 1.2 kb HindIIIHindIII fragment was ligated to the HindIII site between the MC1-Neo and the TK -PKG genes to form the 3 0 homology region. The long-and short-homologous arms of prosaposin gene fragments were divided within an intron (Fig. 1) . The targeting vector was linearized by NotI and electroporated into 2 Â 10 7 ES cells derived from 129/SvEv strain, and stably transfected ES cell clones were isolated after double selection with G418 and Ganciclovir. Homologously recombined ES cell clones were identified by PCR using the primers from the 3 0 end of the Neo gene, 5 0 -CTTCTATCGCCTTCTT GACGAG-3 0 , and just outside the short arm of the targeting vector, 5 0 -CTAGGTCCATTTAACTGCACAGG-3 0 , indicated by arrows in Figure 1 . A 1428 bp PCR product was generated from the recombinant ES cell clones and those were confirmed by Southern blot analysis using the combination of BglII and XhoI digestion with the 5 0 probe located outside of the targeting vector to identify correctly targeted ES cell clones before and after Cre-treatment, and to confirm subsequent mutant mice. Correctly targeted clones were transiently transfected with 20 mg of a CMV promoter -Cre expression, developed in the UNC Animal Models Core Facility, to remove the Neo cassette, and the result confirmed by PCR and Southern blot analysis. Positive mutant clones were used to produce chimeric animals by microinjection into C57BL/6J blastocysts. Male chimeras were then mated with female C57BL/6J mice and heterozygous F 1 mice (saposin D þ/2 ) were then intercrossed to generate saposin D 2/2 mice in a 129SvEv-C57BL/6J mixed background. Two independent lines of saposin D 2/2 mutants were generated from two separate targeted ES cells.
Southern blot and PCR genotyping analysis. We used 473 bp PCR fragments amplified by the primers (forward primer; 5 0 -GCTGGCCCTCTGATTTTAGTTAGT-3 0 and reverse primer; 5 0 -TACCCAGTGAGCTGTCCCTAAGA-3 0 ), which contain intron 1, located outside of the targeting vector as a 5 0 probe to identify correctly targeted ES cell clones before and after Cre-treatment, and to confirm subsequent mutant mice (Fig. 1 ). An aliquot of 10 mg of amplified genomic DNA was digested with BglII and XhoI, and subjected to 0.8% agarose gel electrophoresis, which were then probed with DIG-labeled 5 0 probe as described previously (9) . The presence of the XhoI site introduced by the targeting vector leads to a change of fragment length from 11.7 kb in wildtype allele to 10.8 kb in the mutant recombinant allele. Single digestion with BglII was also used to detect the correct Neo insertion and excision before and after the Cre-treatment.
Heterozygous F 2 saposin D þ/2 mice on the 129SvEv-C57BL/6 mixed background were intercrossed to generate saposin D 2/2 mice. The genetic status for the saposin D mutation was determined by diagnostic PCR on genomic DNA extracted from clipped tails around 7 days postnatally. For genotype analysis of saposin D 2/2 mice, we designed two oligonucleotide primers to distinguish the mutant allele from the wild-type allele by PCR using genomic DNA extracted from the tip of the clipped tail. The oligonucleotide primers were designed to flank the retained one loxP site in intron 14 of the mouse prosaposin gene (sense, 5 0 -ATGGTCCCTGCCTCTGCACAAG-3 0 and antisense, 5 0 -GCTGACTCACGTCCCTGAGAAGGAA-3 0 ), indicated by arrows (Fig. 1) . The PCR product of the wild-type allele was a 216 bp fragment, whereas the PCR product of the mutant allele was a 323 bp fragment.
Semiquantitative RT -PCR. Total RNA was extracted from the whole brain tissues from saposin D 2/2 , saposin D þ/2 , wild-type and prosaposin 2/2 mice. RT -PCR to see the expression of mouse prosaposin and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was evaluated by semiquantitative RT -PCR as described previously (9) .
Animal care
All animals were kept in a pathogen-and odor-free environment, which was maintained under 12 h light/dark cycle at ambient temperature (24 + 18C), and food and water were available ad libitum. The present study was carried out in accordance with the Guidelines for the Care and Use of Laboratory Animal adopted by the Committee on Animal Research in The University of Tokushima, and also accredited by the Japanese Ministry of Education, Culture, Sports, Science and Technology. Every effort was taken carefully to minimize any pain or discomfort of animals used in all experiments.
Clinical observation
In order to follow the course of the disease, all mice were closely observed throughout their lives. Body weight was recorded once a day as an objective parameter for development and progression of the disease. Water intake and urine volume were measured using the metabolic cage (Nalge NUNC International, Tokyo, Japan) according to the manufacture's protocol (53) . To determine the survival time, some mice were allowed to live as long as they could be maintained humanely according to the acceptable practice of laboratory animal care but without forced feeding or other extraneous interventions. More than 10 mice from each group were sacrificed at around 1, 2, 4, 6 and 12 months, for pathological and biochemical evaluation. Samples for biochemical analyses were stored at 2808C until analyses.
Motor coordination tests. Footprint patterns of wild-type mice and saposin D 2/2 mice were analyzed using narrow tunnel (10 cm wide, 35 cm long and 10 cm high) with white paper at the bottom. Before traversing the tunnel, the hind-and forepaws of the animals were dipped in non-toxic blue and red ink, respectively (54) .
The runway test was performed using narrow horizontally fixed beam (1 cm wide, 100 m long, held at a height of 40 cm from the table) (54) . The animal was placed at one end of the beam and allowed to move toward the opposite end where an escaped platform was located. Slips of the forepaw and hindpaw were counted.
Histopathological analysis
Tissue preparation. The mice were anesthetized with sodium pentobarbital and perfused through the left cardiac ventricle with physiological saline, followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4 and immersed in the same fixative at 48C overnight. Then the brain, spinal cord, trigeminal and sciatic nerves, liver, spleen, kidney and testis were dissected and processed for paraffin sections and immunohistochemical studies.
Histopathology and immunohistochemistry. The paraffin sections of the central and peripheral nervous system tissues and liver, spleen, kidney and testis were stained with hematoxylin and eosin and with luxol fast blue/periodic acid Schiff (LFB -PAS).
For free-floating immunohistochemical studies, the brain was sliced in coronal and parasagittal direction at 50 mm thickness with a Microslicer (DTK-1000, Dosaka). The sections were pretreated with 3% H 2 O 2 in 80% methanol for 30 min to reduce the endogenous peroxidase activities and to increase the penetration of antibodies. The sections were incubated in the primary antibodies for 1-3 days at 208C, then in the second antibodies for 2 h. Primary antibodies used for the study were as follows: anti-calbindin D-28k (mouse monoclonal or rabbit polyclonal, 1: 2000; Swant, Switzerland, a Purkinje cell marker), anti-GAD 65/67 (rabbit, 1: 2000; Sigma, St Louis, MO, USA, a GABAneuron marker) and anti-S100b [mouse monoclonal (Sigma) or goat polyclonal (Santa Cruz, Santa Cruz, CA, USA), 1 : 2000, astrocyte markers]. The secondary antibodies used for the study were species specific secondary antibodies biotinylated or tagged with Cy-3, Cy-5 or FITC (Vector Laboratory, Burlingame, CA, USA). All the secondary antibodies were used at 1 : 200 dilution. Hoechst or propidium iodide (PI) staining was alternatively performed for DNA staining. For detection of the biotinylated secondary antibodies, we used the avidin -biotin complex (ABC) method with diaminobenzidin tetrahydroxychloride (DAB) for staining of single antibody (Vector). For multiple staining, with fluorolabeled secondary antibodies, confocal microscopic analysis was employed as described previously (55, 56) . Briefly, immunostained sections were mounted in Vectashield (Vector Laboratory) and examined with a confocal laser scanning microscope (CSLM; Bio-Rad Radiance 2000MP and 2000, Bio-Rad Laboratories, Hercules, CA, USA; mounted on a Nikon TE2000, E800) using laser beams of 345, 494, 554 and 649 nm for excitation with an appropriate filter set. The images were processed with Adobe Photoshop 6.0. The images were not digitally manipulated beyond the general adjustments.
Lipid analyses
Lipid extraction from tissues and thin-layer chromatography (TLC). Tissues (brain, liver and kidney) from male mice were homogenized with ice-cold water at 20% of concentration by weight in an all-glass Potter -Elvehjem homogenizer. Initial extraction with chloroform-methanol was done as described previously (8, 57) . Alternatively, tissues were extracted with 19 volumes of chloroform-methanol 2 : 1 (v/v) and with 10 volumes of chloroform-methanolwater 60 : 120 : 9 (v/v/v) successively (28, 58) . The pooled total lipid extract was analyzed by TLC as described subsequently. A part of the brain total lipid extract was fractionated to neutral and acidic fractions using the reverse phase column essentially according to Kyrklund's method (59) (Bond Elute C-18; 3 ml/500 mg, Varian Inc., Palo Alto, CA, USA). Aliquots of the neutral lipid fraction were subjected to the mercuric chloride-saponification procedure in order to remove essentially all glycerophospholipids (60) . TLC was done with Merck high performance TLC plates (Silica gel 60, Merck, Darmstadt, Germany), with the solvent system, chloroform -methanol -acetic acid 47 : 1: 2 (v/v/v). For analysis of the total lipid extract, the plate was first developed with chloroform -methanol 97: 3 (v/v), thoroughly dried in vacuo, and then developed with chloroform-methanol -acetic acid 47 : 1 : 2 (v/v/v) to avoid interference from the large amount of other lipids. The total lipid extract was also analyzed by two-dimensional TLC using the solvent systems, chloroformmethanol 93 : 7 (v/v) (first direction) and chloroformmethanol -acetic acid 47: 1 : 2 (v/v/v) (second direction). The bands were visualized with 3% cupric acetate -phosphoric acid and determined by densitometry (CS-9000, Shimadzu, Kyoto, Japan) (28, 58) by comparison with known amounts of authentic ceramide (ceramide natural mixture, bovine brain, Funakoshi, Tokyo, Japan).
Identification of ceramides by mass spectrometry. Ceramide bands on the TLC plate were identified by negative-ion liquid secondary ion mass spectrometry (61) . Each band developed by two-dimensional TLC and stained with primuline reagent was transferred to a polyvinylidene difluoride (PVDF) membrane by iron-blotting (Far-eastern blotting) (62) , and the band on the membrane was excised and placed on a mass spectrometry probe tip with triethanolamine as the matrix. Spectra were recorded at an accelerating voltage of 8 kV, with a scan rate of 5 s/decade, and at a resolution of 1000 -2000 on a Concept IH mass spectrometer (ShimadzuKratos, Kyoto, Japan) (63) .
Identification for purified samples was also performed by negative-ion electrospray ionization mass spectrometry using an LCQ DECA ion trap mass spectrometer (ThermoFinnigan, San Jose, CA, USA) (64) . The total lipid extracts prepared from the kidney and brain (0.1 g wet tissue) were separated by TLC as described earlier. The plate was sprayed with primuline reagent. The band corresponding to each molecular species of ceramides was scraped and the lipid was eluted with chloroform -methanol 85: 15 and 3 : 1 (v/v). Solvent volumes were then adjusted to the ratio for the standard Folch partition (chloroform -methanol -0.88% KCl 8 : 4: 3, v/v/v). The lower phase was dried under a gentle stream of nitrogen and redissolved in 0.2 ml of chloroform -methanol 2 : 1 (v/v). An aliquot was diluted with 10-20 volumes of methanol and was directly infused into the ion source at a flow rate of 3 ml/min. The heated capillary was set at 2508C and the spray voltage was set at 5.0 kV. The sheath gas flow rate was set to 50 in arbitrary units. Low energy collisioninduced dissociation was carried out on the molecularrelated ions (MS 2 ) using helium gas present in the ion trap. The relative collision energy used ranged from 35 to 40%.
